BA
SANA icon

Bristlecone Advisors’s Sana Biotechnology SANA Stock Holding History

Bristlecone Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-50,000
Closed -$137K – 288
2025
Q2 		$137K Hold
50,000
– – 0.01% 229
2025
Q1 		$84K Hold
50,000
– – 0.01% 300
2024
Q4 		$81.5K Hold
50,000
– – 0.01% 299
2024
Q3 		$208K Buy
+50,000
New +$263K 0.02% 277

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bristlecone Advisors's SANA Position: Q3 2025 in Review

Bristlecone Advisors sold out of Sana Biotechnology (SANA) in Q3 2025, closing a stake of 50,000 shares — an estimated $137K sold.

Bristlecone Advisors first reported a position in SANA in Q3 2024 and held it in 4 quarters. The position peaked at $208K in Q3 2024. 178 funds tracked by Wall St. Rank hold SANA as of Q3 2025.

  • Bristlecone Advisors reported no remaining Sana Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Bristlecone Advisors sold 50,000 Sana Biotechnology shares in Q3 2025, an estimated $137K.
  • Bristlecone Advisors first reported a position in Sana Biotechnology in Q3 2024 and held it in 4 quarters.
  • Bristlecone Advisors's Sana Biotechnology position peaked at $208K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Sana Biotechnology as of Q3 2025.

Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.